A Delaware federal jury found Monday one genetic testing company must pay nearly $45 million to another for false advertising.

Following a five-day trial, the jury determined Texas-based Natera Inc. is liable for nine of the 10 false advertising claims brought by competitor CareDx Inc. for messaging indicating Natera's kidney transplant rejection test was superior to CareDx's.